secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003922
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 1.02, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure prelim Q4 rev $106.5M (+21% YoY); new $125M ABL credit facility
------------------------------------------------------------------------

- Q4 2023 preliminary revenue $106.5M (+21% YoY); full year revenue $399.2M (+21% YoY).
- FY2023 adj EBITDA guided $18-20M; adj loss per share ~$0.74-$0.76.
- FY2024 revenue guidance $459-466M (15-17% growth); adj EBITDA $26-29M.
- New $125M ABL credit facility (up to $165M) replaces SVB facility, enhances liquidity.
- CEO cites strong Hybrid AF therapy growth; company positioned for robust 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000119312524003922/0001193125-24-003922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000119312524003922/d692835d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer